Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up

B Jordan, A Margulies, F Cardoso, G Cavaletti, H S Haugnes, P Jahn, E Le Rhun, M Preusser, F Scotté, M J B Taphoorn, K Jordan, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, EONS Education Working Group. Electronic address: eons.secretariat@cancernurse.eu, EANO Guideline Committee. Electronic address: office@eano.eu, B Jordan, A Margulies, F Cardoso, G Cavaletti, H S Haugnes, P Jahn, E Le Rhun, M Preusser, F Scotté, M J B Taphoorn, K Jordan, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, EONS Education Working Group. Electronic address: eons.secretariat@cancernurse.eu, EANO Guideline Committee. Electronic address: office@eano.eu

No abstract available

Keywords: CIPN; Clinical Practice Guidelines; central neuropathy; diagnosis; peripheral neurotoxicity; treatment.

Conflict of interest statement

Disclosure BJ has reported advisory board and/or honoraria for presentations for Alexion Pharmaceuticals, Temmler (Hormosan Pharma), Novartis, Biomarin, Merz Pharmaceuticals, Ipsen Pharma and Allergan; FC has reported consultancy role for Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, MacroGenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre Fabre, prIME, Roche, Sanofi, Seattle Genetics and Teva; GC has reported financial interests, honoraria for speaker, consultancy or advisory role and/or institutional research funding from Toray, Disarm, Helsinn, PledPharma, Mundipharma, Kedrion and Chiesi; PJ has reported travel support from Helsinn, consulting or advisory role for Bristol-Myers Squibb, Chugai, Norgine, Helsinn and Clinigen and research grant from Chugai; ELR has received research grants from Mundipharma and Amgen, honoraria for lectures or advisory board from Tocagen, AbbVie, Daiichi Sankyo, Mundipharma and Novartis; MP has received honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb, Novartis, Gerson Lehrman Group, CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, AstraZeneca, AbbVie, Lilly, MEDahead, Daiichi Sankyo, Merck Sharp & Dohme and has reported research funding from Bristol-Myers Squibb, Böhringer-Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme and Roche; FS has reported financial interests, honoraria for speaker, consultancy or advisory role, royalties, direct research funding from Tesaro, Helsinn, Vifor, Merck Sharp & Dohme, Roche, Amgen, Pierre Fabre Oncology, Pfizer, Leo Pharma, Arrow and Bristol-Myers Squibb; KJ has reported financial interests, honoraria for speaker, consultancy or advisory role, royalties and direct research funding from Merck Sharp & Dohme, Merck, Amgen, Hexal, Riemser, Helsinn, Tesaro, Kreussler, Voluntis, Pfizer, POMME-med, PharmaMar, priME Oncology and Onko Solutions; all remaining authors have declared no conflicts of interest.